Austin, TX – April 15, 2025 

Akexis, a clinical-stage biopharmaceutical company pioneering therapies for cancer cachexia, proudly announces the publication of a pivotal article by its Founder and Chief Scientific Officer, Dr. Lingbing Zhang, in the Archives of Clinical and Biomedical Research.

Co-authored with Akexis Chief Medical Officer, Dr. Philip D. Bonomi, the article titled “Treating Cancer Cachexia Should Be Essential in Cancer Care” calls for a fundamental shift in how late-stage cancer care is delivered. The paper highlights that cancer cachexia - a complex, immune-driven syndrome characterized by muscle wasting, systemic inflammation, and metabolic dysfunction - affects up to 80% of advanced cancer patients and is directly responsible for approximately 30% of cancer-related deaths.

“Cancer cachexia is not an inevitable consequence of tumor growth - it is a treatable complication and a leading cause of mortality in advanced cancer,” said Dr. Zhang. “It is long past time we treat it as a core focus in cancer care, not an afterthought.”

Despite its prevalence and impact, there are currently no FDA-approved therapies for cancer cachexia. The paper advocates for incorporating routine screening tools such as the GLIM criteria and the Cachexia Score (CASCO), as well as developing immune-targeted treatments that address the root causes of the condition.

The authors urge the oncology community to move beyond palliative approaches and instead pursue disease-modifying strategies through immunomodulation to improve both quality of life and survival outcomes.

The publication reflects the mission of Akexis: to develop the first effective treatment for cancer cachexia and establish a new standard of care for patients facing the most advanced stages of cancer.

The full article is available at:
Fortune Journals – Archives of Clinical and Biomedical Research

About Akexis
Akexis is a biopharmaceutical company advancing immune-modulating therapies to treat cancer cachexia - an underrecognized but deadly complication that affects the majority of patients with late-stage cancer. Akexis is developing novel treatments aimed at reversing the immune dysfunction that drives cachexia, with the goal of improving patient outcomes, treatment response, and survival.

Media Contact:
Cassie Bernhardt
Chief Development Officer
Cassie@akexis.com | www.akexis.com